Sorsby’s fundus dystrophy: What does TIMP3 tell us about general mechanisms underlying macular degeneration?

Clinical and Experimental Optometry

Volumn 82, Issue 4, 1999, Pages 124-129

  Tymms, Martin J ^a  

^a NATIONAL VISION RESEARCH INSTITUTE   (Australia)

Author keywords

Age related macular degeneration; Choroidal neovascularisation; Retinal pigment epithelium

Indexed keywords

EID: 0038851520     PISSN: 08164622     EISSN: 14440938     Source Type: Journal    
DOI: 10.1111/j.1444-0938.1999.tb06789.x     Document Type: Article

References (25)

1. Klein BE, Klein R., Linton KL. The prevalence of age-related maculopathy: The Beaver Dam Eye Study. Ophthalmology 1992; 99: 933–943.
2. Weber BH, Vogt G., Pruett RC, Stohr H., Felbor U. Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby’s fundus dystrophy. Nat Genet 1994; 8: 352–356.
3. Tabata Y., Isashiki Y., Kamimura K., Nakao K., Ohba N. A novel splice site mutation in the tissue inhibitor of the metalloproteinases-3 gene in Sorsby’s fundus dystrophy with unusual clinical features [In Process Citation]. Hum Genet 1998; 103: 179–182.
4. De La Paz MA, Pericak-Vance MA, Lennon F., Haines JL, Seddon JM. Exclusion of TIMP3 as a candidate locus in age-related macular degeneration. Invest Ophthalmol Vis Sci 1997; 38: 1060–1065.
5. Fernandez-Catalan C., Bode W., Huber R. et al. Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor. EMBO J 1998; 17: 5238–5248.
6. Vranka JA, Johnson E., Zhu X. et al. Discrete expression and distribution pattern of TIMP-3 in the human retina and choroid. Curr Eye Res 1997; 16: 102–110.
7. Apte SS, Olsen BR, Murphy G. The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family. J Biol Chem 1995; 270: 14313–14318.
8. Anand-Apte B., Bao L., Smith R. et al. A review of tissue inhibitor of metalloproteinases-3 (TIMP-3) and experimental analysis of its effect on primary tumor growth. Biochem Cell Biol 1996; 74: 853–862.
9. Delia NG, Campochiaro PA, Zack DJ. Localization of TIMP-3 mRNA expression to the retinal pigment epithelium. Invest Ophthalmol Vis Sci 1996; 37: 1921–1924.
10. Fariss RN, Apte SS, Olsen BR, Iwata K., Milam AH. Tissue inhibitor of metalloproteinases-3 is a component of Bruch’s membrane of the eye. Amer J Pathol 1997; 150: 323–328.
11. Fariss RN, Apte SS, Luthert PJ, Bird AC, Milam AH. Accumulation of tissue inhibitor of metalloproteinases-3 in human eyes with Sorsby’s fundus dystrophy or retinitis pigmentosa. Brit J Ophthalmol 1998; 82: 1329–1334.
12. Langton KP, Barker MD, McKie N. Localization of the functional domains of human tissue inhibitor of metalloproteinases-3 and the effects of a Sorsby’s fundus dystrophy mutation. J. Biol Chem 1998; 273: 16778–16781.
13. Jomary C., Neal MJ, Iwata K., Jones SE. Localization of tissue inhibitor of metalloproteinases-3 in neurodegenerative retinal disease. Neuroreport 1997; 8: 2169–2172.
14. Kliffen M., Sharma HS, Mooy CM, Kerkvliet S., de Jong PT. Increased expression of angiogenic growth factors in age-related maculopathy. Brit J Ophthalmol 1997; 81: 154–162.
15. Hirase K., Ikeda T., Sotozono C., Nishida K., Sawa H., Kinoshita S. Transforming growth factor beta2 in the vitreous in proliferative diabetic retinopathy. Arch Ophthalmol 1998; 116: 738–741.
16. Su GH, Ip HS, Cobb BS, Lu MM, Chen HM, Simon MC. The Ets protein Spi-B is expressed exclusively in B cells and T cells during development. J Exp Med 1996; 184: 203–214.
17. Airola K., Ahonen M., Johansson N. et al. Human TIMP-3 is expressed during fetal development, hair growth cycle, and cancer progression. J Histochem Cytochem 1998; 46: 437–447.
18. Cornelius LA, Nehring LC, Harding E. et al. Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol 1998; 161: 6845–6852.
19. O’Reilly MS, Holmgren L., Shing Y. et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma [see comments]. Cell 1994; 79: 315–328.
20. Felbor U., Stohr H., Amann T., Schonherr U., Weber BH. A novel Ser156Cys mutation in the tissue inhibitor of metalloproteinases-3 (TIMP3) in Sorsby’s fundus dystrophy with unusual clinical features. Hum Mol Genet 1995; 4: 2415–2416.
21. Felbor U., Doepner D., Schneider U., Zrenner E., Weber BH. Evaluation of the gene encoding the tissue inhibitor of metalloproteinases-3 in various maculopathies. Invest Ophthalmol Vis Sci 1997; 38: 1054–1059.
22. Jacobson SG, Cideciyan AV, Regunath G. et al. Night blindness in Sorsby’s fundus dystrophy reversed by vitamin A. Nat Genet 1995; 11: 27–32.
23. Felbor U., Stohr H., Amann T., Schonherr U., Apfelstedt-Sylla E., Weber BH. A second independent Tyr168Cys mutation in the tissue inhibitor of metalloproteinases-3 (TIMP3) in Sorsby’s fundus dystrophy. J Med Genet 1996; 33: 233–236.
24. Peters AL, Greenberg J. Sorsby’s fundus dystrophy. A South African family with a point mutation on the tissue inhibitor of metalloproteinases-3 gene on chromosome 22. Retina. 1995; 15: 480–485.
25. Carrero-Valenzuela RD, Klein ML, Weleber RG, Murphey WH, Litt M. Sorsby fundus dystrophy. A family with the Ser181Cys mutation of the tissue inhibitor of metalloproteinases 3. Arch Ophthalmol 1996; 114: 737–738.